First Annual Conference on the State of the Science on Development and Use of New Approach Methods (NAMs) for Chemical Safety Testing
In 2019, EPA committed to developing and implementing a work plan to reduce the use of animals in chemical testing and to prioritize ongoing efforts, and to direct existing resources, toward additional activities that will demonstrate measurable impacts in the reduction of animal testing while ensuring protection of human health and the environment. To report progress on these activities, EPA hosts regular conferences to provide updates and solicit input from interested stakeholders.
On this page:
- Conference Background
- Logistical Details
- Conference Agenda and Materials
- First Annual Conference Report
EPA’s Office of Chemical Safety and Pollution Prevention (OCSPP) and Office of Research and Development (ORD) hosted the First Annual Conference on the State of the Science on Development and Use of New Approach Methods (NAMs) for Chemical Safety Testing.
This conference was one of EPA’s commitments as set forth in the "Directive to Prioritize Efforts to Reduce Animal Testing" memorandum Administrator Andrew Wheeler signed on September 10, 2019 calling for the Agency to reduce its use of mammalian studies. EPA Administrator, Andrew Wheeler, and OCSPP Assistant Administrator Alexandra Dunn addressed the group.
- Establishing Baselines for Animal Use at EPA and Opportunities for Reduction
- Variability and Relevance of Current Animal Tests and Expectations for NAMs
- State of the Science in Development and Application of NAMs
- Developing Scientific Confidence in NAMs
- Breakout Discussions
- Alternative Test Methods and Strategies to Reduce Vertebrate Animal Testing
- Efforts to Reduce Animal Testing at EPA
The conference was held December 17, 2019.
The Conference was held in EPA’s William Jefferson Clinton East Building at Headquarters in Washington, D.C. and made available by webinar.
Please contact ICF, the organizing contractor with questions about Conference proceedings.
- Email EPA-Workshops@icf.com
|1.||Retrospective analysis of the statutory requirements, study requests, and research utilization in OCSPP and ORD||Anna Lowit||EPA|
|3.||Katie Paul Friedman||EPA|
Integrated Laboratory Systems
|5.||Application of NAMs for quantitative screening level risk decisions||Tara Barton-Maclaren||Health Canada|
Proctor & Gamble
National Institutes of Health